



National Security Commission
on Emerging Biotechnology

Charting the Future of Biotechnology

Presentation for

BPIA Annual Meeting

March 6 | National Biotechnology Policy Panel

Hannah Kelley, Senior Advisor





NSCEB Commissioners



Sen. Todd Young
(IN, Chair)



Dr. Michelle Rozo
Vice Chair



Sen. Alex Padilla
(CA)



Rep. Stephanie Bice
(OK-05)



Rep. Ro Khanna
(CA-17)



Paul Arcangeli



Dr. Angela Belcher



Dawn Meyerriecks



Dr. Eric Schmidt



Dr. Alexander Titus



Dr. Dov Zakheim

NSCEB's Timeline



March 2023
NSCEB established by
NDAA 2022

December 2023
NSCEB Interim Report
published


April 2025
NSCEB Action Plan
published

December 2026
NSCEB authority expires



Why Biotechnology?

**Biotechnology,
particularly combined
with artificial intelligence,
is the next
transformative leap
for human innovation.**



- ▶ To date, most biotechnology breakthroughs have been driven by the United States.

For the last 20 years, the CCP has been strategically investing behind the scenes.

And the results are starting to show.

The United States must take swift action to remain dominant and capture this moment.



Biotechnology offers tremendous potential for good.

However, it can also be misused.

We must be the ones driving the standards for how biotechnology is developed and used in the future.

Top Line



The U.S. government should commit ***\$15 billion over the next five years*** to unleash private capital and innovation into the biotechnology sector.



Report Findings

Key Findings

- 1. Without U.S. action, China will lead global biotech.**
- 2. Biotechnology can break China's supply chain grip.**
- 3. Biomanufacturing is key to reviving manufacturing in every state.**
- 4. Biotechnology is the future of defense.**
- 5. The United States can unleash private innovation with effective governance.**





Policy Recommendations



Policy Objectives



Prioritize Biotechnology at the National Level



Mobilize the Private Sector to Get U.S. Products to Scale



Maximize the Benefits of Biotechnology for Defense



Out-Innovate Our Strategic Competitors



Build the Biotechnology Workforce of the Future



Mobilize the Collective Strengths of Our Allies and Partners



Prioritize Biotechnology at the National Level

Recommendations

- **Establish a National Biotechnology Coordination Office (NBCO)** in the Executive Office of the President to coordinate interagency actions on biotechnology competition and regulation
 - *Introduced as H.R. 2756/S.1387 The National Biotechnology Initiative Act*
- **Designate a senior official in each relevant agency** to lead biotechnology policy
- **Establish the Office of Global Competition Analysis** to develop timely data and technology foresight to inform policymakers' decisions





Mobilize the Private Sector to get U.S. Products to Scale

Recommendations

- Simplify product regulation for biotechnology companies
- Attract private capital to support biotechnology
- Scale up and de-risk manufacturing
- Protect critical biotechnology infrastructure
- Fight back against the PRC's "brute force economics"





Progress Since April 2025




21
provisions signed
into law, including
17 NDAA provisions




over **50**
members of the bipartisan
House BIotech Caucus



150+
NSCEB media mentions
since April 2025



18 states visited in the
#BiotechAcrossAmerica Roadshow



3 new
discussion papers

as of January 2026

Next Steps

Through our December 2026 remit, the Commission will continue to work with Congress and the Administration to pass and implement the recommendations outlined in the report.

